Basilea reported good momentum in H121 in all parts of the business. While total revenues declined to CHF54.2m (reflecting the phasing out of deferred revenues booked), actual in-market sales of Cresemba (severe mould infections) and Cresemba related income increased. Management has thus upgraded FY21 guidance for revenue to CHF134–144m (vs CHF128–138m) and operating loss to CHF7–17m (vs prior expected loss of CHF13–23m). [mehr]
0 comments:
Post a Comment